Genetic variation in the HR region of the env gene of HIV: A perspective for resistance to HIV fusion inhibitors

AIDS Research and Human Retroviruses

Volumn 27, Issue 1, 2011, Pages 57-63

  Qadir, M I ^a   Malik, S A ^b  

^a GC UNIVERSITY   (Pakistan)

^b QUAID I AZAM UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

C 30; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; NUCLEOTIDE; UNCLASSIFIED DRUG; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENVELOPE GENE; GENE MUTATION; GENETIC VARIABILITY; HEPTAD REPEAT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYDROPHOBICITY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN STRUCTURE; VIRUS ISOLATION;

GENE PRODUCTS, ENV; GENETIC VARIATION; GENOTYPE; HIV; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 78651460027     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0098     Document Type: Article

References (24)

1. Qadir MI and Malik SA: HIV fusion inhibitors. Rev Med Virol 2010;20:23-33.
2. Lewis P, Hensel M, and Emerman M: Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 1992;11:3053-3058.
3. Lassen KG, Lobritz MA, Bailey JR, Johnston S, and Nguyen S: Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog 2009;5(4):e1000377.
4. McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, Reyes GR, and Weissman IL: Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 1988;53:55-67.
5. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, and Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997;387:426-430.
6. Qadir MI, Malik SA, Nisa TU, Tabassum N, Ali S, and Nisar L: Characterization of HR region of gp41 of HIV. Int J Agric Biol 2010;12:456-458.
7. Chan DC, Fass D, Berger JM, and Kim PS: Core structure of gp41 fromtheHIV envelope glycoprotein.Cell 1997;89:263-273.
8. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, and Merigan TC: A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000;14:F83-F93.
9. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R, and De Luca A: Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 2002;16(3): 369-379.
10. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vizinet F, Clavel F, and Girard P-M: Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 2002;16:727-736.
11. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C, and Clotet B: Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. AIDS 2002;16(2):209-218.
12. Ivanoff LA, Dubay JW, Morris JF, Roberts SJ, Gutshall L, Sternberg EJ, Hunter E, Matthews TJ, and Petteway SR Jr: V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology 1992;187(2):423-432.
13. Wolf E: HIV drug resistance. 2005. com/textbook/rt.html, retrieved on 11-09-09.
14. Wolf E: HIV resistance testing. In: HIV Medicine 2006 (Hoffmann C, Rockstroh JK, and Kamps BS, Eds.). Flying Publisher, Paris, 2006, pp. 331-356.
15. Champe PC and Harvey RA: Structure of proteins. In: Lippincott's Illustrated Review: Biochemistry, 2nd ed. J.B. Lippincott Company, Philadelphia, 1994, pp. 13-24.
16. Young L, Jernigan RL, and Covell DG: A role for surface hydrophobicity in protein-protein recognition. Protein Sci 1994;3:717-729.
17. Jones S and Thornton JM: Principles of protein-protein interactions. Proc Natl Acad Sci USA 1996;93:13-20.
18. Kazmierski WM, Kenakin TP, and Gudmundsson KS: Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4. Chem Biol Drug Des 2006;67:13-26.
19. Melby T, Heilek G, Cammack N, and Greenberg ML: Resistance to enfuvirtide and other HIV entry inhibitors. In: Antimicrobial Drug Resistance (Mayers DL, Ed.). Humana Press, LLC, Totawa, NJ, 2009, pp. 493-506.
20. Sista PR, Melby T, Davison D, Jin L, Mosier S, Mink M, Nelson EL, DeMasi R, Cammack N, Salgo MP, Matthews TJ, and Greenberg ML: Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004;18:1787-1794.
21. Dorn J, Masciotra S, Yang C, Downing R, Biryahwaho B, Mastro TD, Nkengasong J, Pieniazek D, Rayfield MA, Hu DJ, and Lal RB: Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection. J Clin Microbiol 2000;38:773-780.
22. Hanna SL, Yang C, Owen SM, and Lai RB: Resistance mutation in HIV entry inhibitors. AIDS 2002;16:1603-1608.
23. Root MJ, Kay MS, and Kim PS: Protein design of an HIV-1 entry inhibitor. Science 2001;291:884-888.
24. Markosyan RB, Leung M, and Cohen FS: The six-helix bundle of HIV Env controls pore formation and enlargement and is initiated at residues proximal to the hairpin turn. J Virol 2009;83(19):10048-10057.